CR/iStock via Getty Images
- The percentage of people on a GLP-1 weight loss medication such as Novo Nordisk’s (NVO) Wegovy (semaglutide) or Eli Lilly’s (NYSE:LLY) Zepbound (tirzepatide) sticking with treatment after a year is on the rise.
- For individuals who started treatment in Q1 2024, 63% of people were still using a GLP-1 a year later, according to data from pharmacy benefit manager Prime Therapeutics. For those who started on a GLP-1 in 2021, the figure was just 33% a year later.
- Prime attributed the boost in staying on therapy to the resolution of shortages of both drugs in 2024.
- However, long-term use of GLP-1s continues to be an issue. Many users of the medications stop using them, often citing side effects as an issue.
- Prime’s data found that only 8% of individuals with obesity without diabetes who started on a GLP-1 were still taking the treatment at three years.
More on Novo Nordisk, Eli Lilly
- Eli Lilly: It Is A Bet On Human Longevity
- Novo Nordisk News Is Bad News For Hims & Hers As GLP-1 Collaboration Terminated – Expect Volatility
- Lilly ADA Investor Presentation
- Eli Lilly’s olomorasib granted orphan drug designation for NSCLC type
- Novo Nordisk gets EU backing for Ozempic label expansion